Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Authors

J.Q. Del Rosso (ORCID: https://orcid.org/0000-0003-4215-7340)
Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
Gaia Gallo
Marta Casillas (ORCID: https://orcid.org/0000-0002-6339-5279)
Gil Yosipovitch (ORCID: https://orcid.org/0000-0001-6303-1822)
Sonja Ständer (ORCID: https://orcid.org/0000-0003-3612-7786)
Peter Lio (ORCID: https://orcid.org/0000-0001-7600-0152)
Yuxin Ding (ORCID: https://orcid.org/0000-0001-8968-9147)
Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
J.M. Carrascosa (ORCID: https://orcid.org/0000-0003-4266-0771)
Andreas Wollenberg (ORCID: https://orcid.org/0000-0003-0177-8722)
Evangeline Pierce (ORCID: https://orcid.org/0000-0002-8287-2835)
Helena Agell
Zhenhui Xu (ORCID: https://orcid.org/0000-0003-0821-1008)

Institutions

Northwestern University (US)
Universitat Autònoma de Barcelona (ES)
University of Miami (US)
Henry Ford Health System (US)
Eli Lilly (United States) (US)
George Washington University (US)
University Hospital Augsburg (DE)
Universitäres Kinderwunschzentrum Lübeck (DE)
University Hospital Münster (DE)
Almirall (Spain) (ES)
Hospital Universitari Germans Trias i Pujol (ES)
Ludwig-Maximilians-Universität München (DE)
University of Lübeck (DE)

Publication Details

Journal: Dermatology and Therapy
Published: 2024-08-01
DOI: https://doi.org/10.1007/s13555-024-01226-9
Citations: 10
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 5.35

Funders

Eli Lilly and Company
Dermira

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

J.Q. Del Rosso, Jonathan I. Silverberg, Gaia Gallo, Marta Casillas et al.

Aug 1, 2024

10 citations

Dermatology and Therapy

Dermatology and Skin Diseases

5.35

article

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

J.Q. Del Rosso, Jonathan I. Silverberg, Gaia Gallo, Marta Casillas, Gil Yosipovitch, Sonja Ständer, Peter Lio, Yuxin Ding, Linda Stein Gold, J.M. Carrascosa, Andreas Wollenberg, Evangeline Pierce, Helena Agell, Zhenhui Xu

August 1, 2024article en

10 citations

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 14(8)

Northwestern University (US), Universitat Autònoma de Barcelona (ES), University of Miami (US), Henry Ford Health System (US), Eli Lilly (United States) (US), George Washington University (US), University Hospital Augsburg (DE), Universitäres Kinderwunschzentrum Lübeck (DE), University Hospital Münster (DE), Almirall (Spain) (ES), Hospital Universitari Germans Trias i Pujol (ES), Ludwig-Maximilians-Universität München (DE), University of Lübeck (DE)

Eli Lilly and Company, Dermira

Openalex Percentile: Top 4%

Dermatology and Skin Diseases

5.35

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment — J.Q. Del Rosso, Jonathan I. Silverberg, et al. · Dermatology and Therapy (2024) | TGRS Research Map | TGRS